Clinical Trial Update: Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17 [Phase 3]

View source ↗

Summary

Phase 3 double-blind, placebo-controlled withdrawal study of LDX in children and adolescents with ADHD completed; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• LDX (lisdexamfetamine)

Snippet

Sponsor: Shire | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2012-10-02